ANIK Anika Therapeutics Inc.

0  -1%
Previous Close 44.47
Open 44.78
Price To book 2.92
Market Cap 644.36M
Shares 14,638,000
Volume 103,964
Short Ratio 8.83
Av. Daily Volume 109,479

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 2014
Additional Phase 3 trial to be initiated 1Q 2017.

Latest News

  1. Anika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3
  2. 6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017
  3. Implied Volatility Surging for Anika Therapeutics (ANIK) Stock Options
  4. Anika to Present at the 2017 Canaccord Genuity Musculoskeletal Conference on March 14, 2017
  5. Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market Opening Bell
  6. Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017
  7. Edited Transcript of ANIK earnings conference call or presentation 16-Feb-17 2:00pm GMT
  8. Anika posts 4Q profit
  9. Anika Reports Fourth Quarter and Full Year 2016 Financial Results
  10. Novartis (NVS) Votubia Gets EU Approval for Label Expansion
  11. Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
  12. Anika to Issue Fourth-Quarter 2016 Financial Results and Business Highlights on Wednesday, February 15
  13. Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval
  14. Allergan (AGN) Avycaz Label to Include New Phase III Data
  15. Exelixis Inks Partnership with Takeda for Cabometyx in Japan
  16. Novo Nordisk Inks Diabetes Deal with University of Oxford
  17. Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
  18. Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
  19. AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA
  20. Immunogen Doses First Patient in Ovarian Cancer Drug Study